798545-30-9 Usage
Uses
Used in Pharmaceutical Industry:
6-Bromoquinoline-3-carboxylic Acid is used as an intermediate compound for the synthesis of various pharmaceutical drugs. Its unique structure and reactivity make it a valuable building block in the development of new medications.
Used in Chemical Research:
6-Bromoquinoline-3-carboxylic Acid is used as a research compound in the field of organic chemistry. Its bromo functional group allows for a wide range of chemical reactions, making it a useful tool for studying reaction mechanisms and exploring new synthetic pathways.
Used in Material Science:
6-Bromoquinoline-3-carboxylic Acid is used as a component in the development of new materials with specific properties. Its incorporation into various materials can lead to improved performance in areas such as electronics, optics, and catalysis.
Used in Biological Research:
6-Bromoquinoline-3-carboxylic Acid is used as a probe in biological studies, particularly in the investigation of enzyme activity and the interaction of molecules with biological targets. Its unique structure allows for the exploration of new biochemical pathways and the development of potential therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 798545-30-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,9,8,5,4 and 5 respectively; the second part has 2 digits, 3 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 798545-30:
(8*7)+(7*9)+(6*8)+(5*5)+(4*4)+(3*5)+(2*3)+(1*0)=229
229 % 10 = 9
So 798545-30-9 is a valid CAS Registry Number.
InChI:InChI=1/C10H6BrNO2/c11-8-1-2-9-6(4-8)3-7(5-12-9)10(13)14/h1-5H,(H,13,14)
798545-30-9Relevant academic research and scientific papers
Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
-
, (2016/04/26)
The present invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth.
COMBINATION OF KINASE INHIBITORS AND USES THEREOF
-
, (2015/02/19)
The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or a receptor tyrosine kinase (RTK) in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or an RTK in a subject. In yet another aspect, a method of inhibiting phosphorylation of Akt (S473) in a cell is set forth.
COMBINATION OF KINASE INHIBITORS AND USES THEREOF
-
, (2014/10/04)
The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth. The present invention also provides a pharmaceutical kit effective for treating a disease condition associated with PI3 -kinase α and/or mTOR in a subject.
